Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for Legend Biotech (LEGN) over the last 5 years, with Sep 2025 value amounting to $2.1 million.

  • Legend Biotech's Depreciation & Amortization (CF) fell 9.87% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year decrease of 11.49%. This contributed to the annual value of $10.7 million for FY2024, which is 0.04% down from last year.
  • Latest data reveals that Legend Biotech reported Depreciation & Amortization (CF) of $2.1 million as of Q3 2025, which was down 6.00% from $2.3 million recorded in Q2 2025.
  • Legend Biotech's 5-year Depreciation & Amortization (CF) high stood at $3.2 million for Q1 2022, and its period low was -$20,000 during Q4 2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $2.7 million (2023), whereas its average is $2.6 million.
  • Within the past 5 years, the most significant YoY rise in Legend Biotech's Depreciation & Amortization (CF) was 12,505.00% (2022), while the steepest drop was 38.93% (2022).
  • Quarterly analysis of 5 years shows Legend Biotech's Depreciation & Amortization (CF) stood at -$20,000 in 2021, then skyrocketed by 12,505.00% to $2.5 million in 2022, then rose by 9.88% to $2.7 million in 2023, then rose by 0.62% to $2.7 million in 2024, then declined by 9.87% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $2.3 million for Q2 2025, and $2.3 million during Q1 2025.